Novartis Science

A new paper sheds light on how the transcription factor BACH1 regulates the oxidative stress response, offering mechanistic insights into a key cellular pathway and potential target in oxidative stress-related diseases such as cancer, autoimmune disorders. novartis.social/6019oZzSU

Novartis, @bioagelabs announce multi-year collaboration to discover novel targets for therapies that address age-related diseases and conditions.

Novartis has entered into a global license and collaboration agreement with @PTCBio for a Huntington’s disease program, currently in Phase II development, with the potential to become the first oral disease-modifying therapy for the disorder. go.novartis.social/3Zx6nQf

Novartis and @RatioTx have entered a license and collaboration agreement to advance a next-generation radioligand therapy to bring additional therapeutic options forward for patients with hard-to-treat cancer. go.novartis.social/3VkWhQj

Novartis and Schrödinger have announced a multi-target research collaboration, and an expanded software agreement that will broaden Novartis access to Schrödinger’s computational predictive modeling technology and enterprise informatics platform. go.novartis.social/3ADLcT7